论文部分内容阅读
目的探讨基于免疫细胞化学技术检测肺癌细针穿刺细胞学传统涂片标本中ALK融合蛋白表达的可行性。方法收集61例肺癌患者的转移淋巴结细针穿刺传统涂片标本,应用免疫细胞化学(ICC)方法,用罗氏Ventana全自动免疫组化仪检测ALK融合蛋白的表达情况,并与相应的荧光原位杂交(FISH)检测结果进行比较。结果 61例细针穿刺传统涂片中,ICC检测ALK融合蛋白阳性表达率为9.9%(6/61),肺腺癌ALK融合蛋白阳性表达率为10.9%(6/55),其他鳞状细胞癌等均阴性(0/6),与相应FISH检测结果比较,符合率为93.8%(15/16)(Kappa=0.871),敏感性为85.7%(6/7),特异性为100%(9/9)。结论对于无法手术或者活检的晚期肺癌患者,细胞学细针穿刺传统涂片标本的ICC检测可以作为肺癌EML4-ALK融合基因FISH检测前的常规筛查手段。
Objective To investigate the feasibility of using immunocytochemistry to detect the expression of ALK fusion protein in traditional smears of fine needle aspiration cytology of lung cancer. Methods Sixty-one patients with metastatic lymph nodes were collected by conventional needle aspiration needle biopsy. The immunocytochemistry (ICC) method was used to detect the expression of ALK fusion protein by Roche Ventana immunohistochemistry. Hybridization (FISH) test results were compared. Results The positive rate of ALK fusion protein expression in ICC was 9.9% (6/61) in 61 cases of fine needle aspiration and 10.9% (6/55) in lung adenocarcinoma. Other squamous cell (0/6). The coincidence rate was 93.8% (15/16) (Kappa = 0.871), the sensitivity was 85.7% (6/7) and the specificity was 100% 9/9). CONCLUSIONS: ICC detection of cytology fine needle aspiration biopsy can be used as a routine screening method before FISH for detecting lung cancer EML4-ALK fusion gene in patients with advanced lung cancer who can not undergo surgery or biopsy.